Y0000472

Cabergoline

European Pharmacopoeia (EP) Reference Standard

• Synonyme(s) : 1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea, 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, Cabaser, Dostinex, FCE-21336
• Formule empirique (notation de Hill) : C₂₆H₃₇N₅O₂
• CAS Number: 81409-90-7
• Poids moléculaire : 451.60
• Numéro MDL: MFCD00867887
• Code UNSPSC : 41116107
• ID de substance PubChem : 329830976
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: pharmaceutical primary standard
• Famille d'API: cabergoline
• Fabricant/nom de marque: EDQM
• Application(s): pharmaceutical (small molecule)
• Format: neat
• Température de stockage: −20°C
• Chaîne SMILES: CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1
• InChI: 1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
• Clé InChI: KORNTPPJEAJQIU-KJXAQDMKSA-N
• Informations sur le gène: human ... DRD2(1813)

Description

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cabergoline EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).

Dopamine D2-receptor agonist; Prolactin inhibitor; Antiparkinsonian

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Informations sur la sécurité

• Pictogrammes: GHS07
• Mention d'avertissement: Warning
• Mentions de danger: H302,H362
• Conseils de prudence: P202 - P260 - P263 - P264 - P301 + P312 - P308 + P313
• Classification des risques: Acute Tox. 4 Oral - Lact.
• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable